Systematic literature review of treatment patterns for venous thromboembolism patients during transitions from inpatient to post-discharge settings

References

• DeitelzweigSBJohnsonBHLinJSchulmanKLPrevalence of clinical venous thromboembolism in the USA: current trends and future projectionsAm J Hematol201186221722021264912
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC)Venous thromboembolism in adult hospitalizations - United States, 2007-2009MMWR Morb Mortal Wkly Rep2012612240140422672974
   PubMedGoogle Scholar
• GrosseSDNelsonRENyarkoKARichardsonLCRaskobGEThe economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costsThromb Res201613731026654719
   PubMed Web of Science ®Google Scholar
• KearonCAklEAOrnelasJAntithrombotic therapy for VTE disease: CHEST guideline and expert panel reportChest2016149231535226867832
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCKakkarAKDabigatran versus warfarin in the treatment of acute venous thromboembolismN Engl J Med2009361242342235219966341
   PubMed Web of Science ®Google Scholar
• EINSTEIN InvestigatorsBauersachsRBerkowitzSDOral rivaroxaban for symptomatic venous thromboembolismN Engl J Med2010363262499251021128814
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAOral apixaban for the treatment of acute venous thromboembolismN Engl J Med2013369979980823808982
   PubMed Web of Science ®Google Scholar
• LenchusJDTransitions in the prophylaxis, treatment and care of patients with venous thromboembolismAdv Ther2016331294526677164
   PubMed Web of Science ®Google Scholar
• PadronMMiyaresMADevelopment of an anticoagulation stewardship program at a large tertiary care academic institutionJ Pharm Pract2015281939824326411
   PubMedGoogle Scholar
• BrockJMitchellJIrbyKAssociation between quality improvement for care transitions in communities and rehospitalizations among Medicare beneficiariesJAMA2013309438139123340640
   PubMed Web of Science ®Google Scholar
• OwensGMFineCHarringtonDWImproving transitions of care for patients with thromboembolic diseaseAm J Manag Care2014204 SupplS819124773398
   PubMedGoogle Scholar
• MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementPLoS Med200967e100009719621072
   PubMed Web of Science ®Google Scholar
• LiberatiAAltmanDGTetzlaffJThe PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaborationPLoS Med200967e100010019621070
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence [homepage on the Internet] The Guidelines ManualLondonNational Institute for Health and Clinical Excellence2009 www.nice.org.ukAccessed November 23, 2018
   Google Scholar
• HusereauDDrummondMPetrouSConsolidated Health Economic Evaluation Reporting Standards (CHEERS)-explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task ForceValue Health201316223125023538175
   PubMed Web of Science ®Google Scholar
• SharifiMFreemanWBayCSharifiMSchwartzFLow incidence of post-thrombotic syndrome in patients treated with new oral anticoagulants and percutaneous endovenous intervention for lower extremity deep venous thrombosisVasc Med201520211211625832599
   PubMedGoogle Scholar
• StreiffMBMilentijevicDMccraeKRecurrent VTE in cancer patients treated with anticoagulationJournal of Clinical Oncology20163415_suppl1002410024
   Google Scholar
• DesaiADesaiACalixteRComparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous ThromboembolismLung2016194460561127192990
   PubMedGoogle Scholar
• SpyropoulosACPreblickRKwongWJLingohr-SmithMLinJIs adherence to the American College of Chest Physicians recommended anticoagulation treatment duration associated with different outcomes among patients with venous thromboembolism?Clin Appl Thromb Hemost201723653254127899520
   PubMedGoogle Scholar
• BeamDMKahlerZPKlineJAImmediate discharge and home treatment with rivaroxaban of low-risk venous thromboembolism diagnosed in two U.S. emergency departments: a one-year preplanned analysisAcad Emerg Med201522778879526113241
   PubMed Web of Science ®Google Scholar
• FalconieriLThomsonLOettingerGFacilitating anticoagulation for safer transitions: preliminary outcomes from an emergency department deep vein thrombosis discharge programHosp Pract20144241645
   Google Scholar
• SteinPDMattaFHughesPGHome Treatment of pulmonary embolism in the era of novel oral anticoagulantsAm J Med2016129997497727107921
   PubMedGoogle Scholar
• CefaloPWeinbergIHawkinsBMA comparison of patients diagnosed with pulmonary embolism who are ≥65 years with patients <65 yearsAm J Cardiol2015115568168625586333
   PubMedGoogle Scholar
• MenzinJPreblickRFriedmanMMenzinJFreanMJacqueline KwongWTreatment patterns and outcomes among hospitalized patients with venous thromboembolism in the United States: an analysis of electronic health records dataHosp Pract20144245974
   Google Scholar
• SteinPDMattaFHughesPGHome treatment of deep venous thrombosis in the era of new oral anticoagulantsClin Appl Thromb Hemost201521872973226239315
   PubMedGoogle Scholar
• CaiJPreblickRZhangQKwongWJUtilization of parenteral anticoagulants and warfarin: impact on the risk of venous thromboem-bolism recurrence in the outpatient settingAm Health Drug Benefits20147844445125558306
   PubMedGoogle Scholar
• DeitelzweigSLalibertéFCriveraCHospitalizations and other health care resource utilization among patients with deep vein thrombosis treated with rivaroxaban versus low-molecular-weight heparin and warfarin in the outpatient settingClin Ther2016388e180318031816
   PubMedGoogle Scholar
• DeitelzweigSKlineJMargolisJMComparison of rivaroxaban or warfarin use for venous thromboembolism on inpatient length of stayJ Am Coll Cardiol206520166713 Supplement
   Google Scholar
• DeitelzweigSRautMKMargolisJHospital length of stay for deep vein thrombosis or pulmonary embolism among patients receiving rivaroxaban or warfarin20–2562015Toronto, ON, CanadaJournal of Thrombosis and Haemostasis Conference: 25th Congress of the International Society on Thrombosis and Haemostasis, ISTH 2015
   Google Scholar
• MerliGJHollanderJELefebvrePRates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxabanHosp Pract20154328593
   Google Scholar
• RobertsKMKnightTBPadilla-TolentinoEMurthyMPetersonEJLength of stay comparison between rivaroxaban and warfarin in the treatment of pulmonary embolism: results from a real-world observational cohort studyThrombosis2015201516
   Google Scholar
• MargolisJMDeitelzweigSKlineJShorter hospital stays and lower costs for rivaroxaban compared with warfarin for venous thrombosis admissionsJ Am Heart Assoc2016510e00378827792638
   PubMedGoogle Scholar
• LaMoriJCShoheiberOModySHBookhartBKInpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United StatesClin Ther2015371627025524389
   PubMedGoogle Scholar
• MargolisJMDeitelzweigSKlineJPulmonary embolism inpatients treated with rivaroxaban had shorter hospital stays and lower costs compared with warfarinClin Ther201638112496250327751675
   PubMed Web of Science ®Google Scholar
• KahlerZPBeamDMKlineJACost of treating venous thromboembo-lism with heparin and warfarin versus home treatment with rivaroxabanAcad Emerg Med201522779680226111453
   PubMed Web of Science ®Google Scholar
• KahlerZPBeamDMKlineJAImmediate discharge of low-risk venous thromboembolism: A cost and safety analysisSAEM 20142014215 Suppl. 1S16S17
   Google Scholar
• ShorrAFJohnstonSJingYReal-world cost of all-cause hospitalizations over a 12-month period after acute venous thromboembolismCirculation2014130
   Google Scholar
• ColemanCIFermannGJWeedaERIs Rivaroxaban associated with shorter hospital stays and reduced costs versus parenteral bridging to warfarin among patients with pulmonary embolism?Clin Appl Thromb Hemost201723783083727481875
   PubMedGoogle Scholar
• WeedaERWellsPSPeacockWFHospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarinIntern Emerg Med201712331131827757790
   PubMedGoogle Scholar
• RaphaelIJMckenzieJCZmistowskiBBrownDBParviziJAustinMSPulmonary embolism after total joint arthroplasty: cost and effectiveness of four treatment modalitiesJ Arthroplasty201429593393724269095
   PubMedGoogle Scholar
• LinJLingohr-SmithMKwongWJIncremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspectiveJ Manag Care Pharm201420217418624456319
   PubMed Web of Science ®Google Scholar
• AminABrunoATrocioJLinJLingohr-SmithMIncremental health care burden of bleeding among patients with venous throm-boembolism in the United StatesJ Manag Care Spec Pharm2015211096597226402395
   PubMedGoogle Scholar
• FanikosJRaoASegerACCarterDPiazzaGGoldhaberSZHospital costs of acute pulmonary embolismAm J Med2013126212713223331440
   PubMed Web of Science ®Google Scholar
• BookhartBKHaskellLBamberLWangMScheinJModySHLength of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial programJ Med Econ2014171069169525065536
   PubMedGoogle Scholar
• DastaJFPilonDModySHDaily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapyThromb Res2015135230331025555319
   PubMed Web of Science ®Google Scholar
• WeedaERKohnCGPeacockWFRivaroxaban versus heparin bridging to warfarin therapy: impact on hospital length of stay and treatment costs for low-risk patients with pulmonary embolismPharmacotherapy201636101109111527548074
   PubMedGoogle Scholar
• MerliGJHollanderJELefebvrePCosts of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarinJ Med Econ2016191849026390315
   PubMed Web of Science ®Google Scholar
• DuboisCLouzonPBhathejaRRivaroxaban vs. standard of care post ultrasound accelerated thrombolysis for pulmonary embolismCritical Care Medicine20154312153
   Google Scholar
• AtayJKFiumaraKPiazzaGFanikosJGoldhaberSZHospital budget implications of substituting dabigatran for warfarin in an anticoagulation serviceClin Appl Thromb Hemost201218218118421873358
   PubMedGoogle Scholar
• AminABrunoATrocioJLinJLingohr-SmithMReal-world medical cost avoidance when new oral anticoagulants are used versus warfarin for venous thromboembolism in the United StatesClin Appl Thromb Hemost201622151125993994
   PubMed Web of Science ®Google Scholar
• AminABrunoATrocioJLinJLingohr-SmithMComparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the USJ Med Econ201518639940925586203
   PubMed Web of Science ®Google Scholar
• ColemanCIBaughCCriveraCHealthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolismJ Med Econ201720220020327780397
   PubMed Web of Science ®Google Scholar
• DeitelzweigSLalibertéFRautRHealth care costs among patients diagnosed with deep vein thrombosis in the outpatient setting and treated with rivaroxaban versus low-molecular-weight heparin and warfarinValue in Health2016193A45A46
   Google Scholar
• AminABrunoATrocioJLinJLingohr-SmithMEstimated savings in medical costs when new oral anticoagulants are used for the treatment of patients with nonvalvular atrial fibrillation and venous thromboem-bolism vs. Warfarin in the U.SValue in Health2015183A138
   Google Scholar
• AminAJingYTrocioJLinJLingohr-SmithMGrahamJEvaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patientsJ Med Econ2014171176377025078794
   PubMedGoogle Scholar
• AminAJingYTrocioJLinJLingohr-SmithMGrahamJEvaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial resultsJ Thromb Thrombolysis201540213113825502587
   PubMedGoogle Scholar
• ChoiMHectorMManagement of venous thromboembolism for older adults in long-term care facilitiesJ Am Acad Nurse Pract201224633534422672484
   PubMedGoogle Scholar
• BashirRZackCJZhaoHComerotaAJBoveAAComparative outcomes of catheter-directed thrombolysis plus anticoagulation vs anticoagulation alone to treat lower-extremity proximal deep vein thrombosisJAMA Intern Med201417491494150125047081
   PubMedGoogle Scholar
• ChenSYWuNGulsethMOne-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent eventsJ Manag Care Pharm201319429130123627575
   PubMed Web of Science ®Google Scholar
• FangMCFanDWittDMThe association of warfarin control with pulmonary embolism mortality: the CVRN VTE studyCirculation2013128suppl_22
   PubMedGoogle Scholar
• JeanGWKellyKMathewJLarumbeEHughesRVenous throm-boembolism treatment outcomes in cancer patients and effect of third-party payers on anticoagulant choiceSupport Care Cancer2017251596627543162
   PubMedGoogle Scholar
• LevyMMBachCFisher-SnowdenRPfeiferJDUpper extremity deep venous thrombosis: reassessing the risk for subsequent pulmonary embolismAnn Vasc Surg201125444244721549911
   PubMedGoogle Scholar
• LiuXXieLPhatakHPersistence on warfarin therapy in patients with venous thromboembolism: a large US insurance database analysisCirculation2013128suppl_22
   Google Scholar
• SussmanMLimJWangCFriedmanMSanderSGriffithsRCharacteristics and treatment patterns of patients with deep vein thrombosis and/or pulmonary embolism in the US hospital settingBlood2015126232061
   Google Scholar
• XieLLiuXPhatakHWarfarin discontinuation in patients with unprovoked venous thromboembolism: a large US insurance database analysisAm J Ther2016236e1744e175326214203
   PubMedGoogle Scholar